Medtronic stock rises 2.34% since latest earnings report

Medtronic stock was quoted at 86.34 EUR by Lang & Schwarz on October 29, 2026, at 4:04:52 p.m. Berlin time. That is 2.34 percent above the 84.37 EUR quote recorded in our latest relevant report on October 27, 2026, at 4:16 p.m. CEST. The comparison is separate from an Xetra daily performance figure, which is not included here.

What has changed since our last report

Medtronic's latest operating update includes real-world registry results presented at the Asia Pacific Heart Rhythm Society 2026 meeting on October 22. In a Medtronic release, the company reported results for the Sphere-9 catheter and PulseSelect pulsed-field ablation system.

The APEX registry covered 1,050 atrial-fibrillation patients treated with Sphere-9 across 28 sites and reported a 1.1 percent major-complication rate. The REAL PULSE registry included 1,160 atrial-fibrillation patients treated with PulseSelect across 38 sites, with a reported 100 percent acute success rate and a 0.09 percent acute major-complication rate. Medtronic also disclosed a separate ventricular-tachycardia analysis involving 46 patients; Sphere-9 is investigational for this indication in the United States.

Portfolio reshaping remains relevant

On October 15, Medtronic completed the separation of MiniMed Group. The company said in its official announcement that it exchanged its remaining 252,813,348 MiniMed shares in an offer that was 5.4 times subscribed. Management described the transaction as a way to give both businesses a clearer strategic focus.

Investors can follow the real-time quote of Medtronic stock. The latest price move provides a fresh market reference after the earnings-focused report, but it does not by itself establish a cause for the performance.

Broader sentiment remains linked to the S&P 500 and the wider healthcare-equipment market.

Further company-specific developments are collected in more news and analyses on Medtronic stock.